Reported positive top-line results from second pivotal Phase 3 trial of FINTEPLA (ZX008) in patients with Dravet syndrome, Study 1504 rare central nervous system (CNS) disorders…
[Read on via official release]
Source: US SEC
View full document:
EX-991_of_8-K_for_ZOGENIX_INC__8-K-11-08-2018
